Search Within

Sergio Andres Giralt

  1. "2021"
Formats
  1. Journal Article (29)
  2. Meeting Abstract (28)
  3. Research Letter (4)
  4. Review (4)
  5. Guidelines (1)
Groups
  1. Bone Marrow Transplant (66)
  2. Center for Hematologic Malignancies (66)
  3. Department of Medicine (66)
  4. Hematologic Malignancies, Division of (66)
  5. Hematology-Oncology Fellows (45)
  6. CTCR Scholars (44)

More Groups

People
  1. Miguel-Angel Perales (31)
  2. Gunjan Shah (23)
  3. Sean Devlin (23)
  4. Michael Scordo (22)
  5. Parastoo Dahi (20)
  6. Craig Sauter (18)

More People

Years
  1. 2021 (66)
Publications
  1. Blood (16)
  2. Transplantation and Cellular Therapy (10)
  3. Bone Marrow Transplantation (5)
  4. Journal of Clinical Oncology (5)
  5. Blood Advances (4)
  6. Clinical Lymphoma, Myeloma and Leukemia (3)

More Publications

Publishers
  1. American Society of Hematology (20)
  2. Elsevier Inc. (13)
  3. Nature Publishing Group (8)
  4. American Society of Clinical Oncology (6)
  5. Churchill Livingstone (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (66)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34(+)-selected allogeneic transplantation
    Journal Article

    Cho, C.; Hilden, P.; Avecilla, S. T.; Barker, J. N.; Castro-Malaspina, H.; Giralt, S. A.; Gyurkocza, B.; Jakubowski, A. A.; Maloy, M. A.; O'Reilly, R. J.; more...
    Advances in Cell and Gene Therapy (2021)

    Fulltext@MSK | Save
  • Clinical experience in the randomized phase 3 Sierra Trial: Anti-CD45 iodine ((131)I) apamistamab [Iomab-B] conditioning enables hematopoietic cell transplantation with successful engraftment and acceptable safety in patients with active, relapsed/refractory AML not responding to targeted therapies
    Meeting Abstract

    Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Koshy, N. V.; Stiff, P.; Abboud, C. Sr; Tomlinson, B.; Abhyankar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study
    Meeting Abstract

    Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study
    Meeting Abstract

    Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post-transplant inotuzumab ozogamicin for acute lymphoblastic leukemia
    Meeting Abstract

    Metheny, L. 3rd; Sobecks, R. M.; Cho, C.; Caimi, P. F.; Majhail, N. S.; Otegbeye, F.; Boughan, K. M.; Cooper, B. W.; Galloway, E.; Gallogly, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save